Table 1.
Baseline characteristics by treatment group
| Placebo (n=214) | Brensocatib (n=190) | ||
|---|---|---|---|
| Mean age, years | 62·0 (14·9) | 62·3 (12·5) | |
| Sex | |||
| Male | 127 (59%) | 125 (66%) | |
| Female | 87 (41%) | 65 (34%) | |
| Ethnicity | |||
| White British | 189 (88%) | 167 (88%) | |
| Irish | 1 (0%) | 2 (1%) | |
| Any other White background | 5 (2%) | 6 (3%) | |
| White and Black Caribbean | 1 (0%) | 0 | |
| White and Black African | 1 (0%) | 0 | |
| Any other mixed or multiple ethnic background | 1 (0%) | 0 | |
| Indian | 5 (2%) | 1 (1%) | |
| Pakistan | 3 (1%) | 4 (2%) | |
| Bangladeshi | 1 (0%) | 0 | |
| Any other Asian background | 2 (1%) | 4 (2%) | |
| African | 0 | 1 (1%) | |
| Any other Black, African, or Caribbean background | 1 (0%) | 0 | |
| Arab | 1 (0%) | 1 (1%) | |
| Any other ethnic group | 3 (1%) | 2 (1%) | |
| Unknown | 0 | 2 (1%) | |
| Smoking status | |||
| Current Smoker | 12 (6%) | 9 (5%) | |
| Never smoked | 98 (46%) | 93 (49%) | |
| Former smoker | 72 (34%) | 67 (35%) | |
| Unknown | 32 (15%) | 21 (11%) | |
| Comorbidities | |||
| Chronic cardiac disease, including congenital heart disease | 37 (17%) | 34 (18%) | |
| Hypertension | 90 (42%) | 70 (37%) | |
| Chronic obstructive pulmonary disease | 22 (10%) | 29 (15%) | |
| Asthma (physician diagnosed) | 38 (18%) | 34 (18%) | |
| Chronic kidney disease (estimated glomerular filtration rate <44 mL/min on dialysis or previous transplant) | 9 (4%) | 7 (4%) | |
| Obesity | 48 (22%) | 41 (22%) | |
| Diabetes with complications | 14 (7%) | 5 (3%) | |
| Diabetes without complications | 33 (15%) | 29 (15%) | |
| Rheumatological disorder | 18 (8%) | 19 (10%) | |
| Median duration of symptoms, days | 8·0 (6·0–11 ·0) | 9·0 (6·0–12·0) | |
| Disease severity | |||
| Required supplemental oxygen | 160 (75%) | 148 (78%) | |
| Peripheral capillary oxygen saturation ≤94% on room air before randomisation | 120 (56%) | 112 (59%) | |
| Radiographic infiltrates by imaging (eg, chest x-ray or CT scan) | 146 (68%) | 138 (73%) | |
| Evidence of rales or crackles on physical examination | 99 (46%) | 101 (53%) | |
| Lymphocyte count less than 1 × 109 cells per L | 95 (44%) | 88 (46%) | |
| Clinical status at randomisation | |||
| Hospitalised and not requiring supplemental oxygen | 50 (23%) | 42 (22%) | |
| Hospitalised and requiring supplemental oxygen | 140 (65%) | 128 (67%) | |
| Hospitalised and on non-invasive ventilation or high flow oxygen devices | 24 (11%) | 20 (11%) | |
| Median 7-point WHO ordinal scale for clinical status | 4 (4–4) | 4 (4–4) | |
| SARS-CoV-2 PCR status | |||
| Confirmed positive SARS-CoV-2 PCR test | 204 (95%) | 186 (98%) | |
| Clinically suspected without confirmed SARS-CoV-2 PCR test | 10 (5%) | 4 (2%) | |
Data are n (%), mean (SD), or median (IQR).